Adicet Bio Inc (ACET)

$7.70 -0.28 (-3.51%)
Market Cap 76.53M
Revenue (ttm) 0.00
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 82,469
Avg Vol 177,348
Day's Range N/A - N/A
Shares Out 9.58M
Stochastic %K 18%
Beta 1.60
Analysts Strong Sell
Price Target $28.25

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 503 9095
Address:
131 Dartmouth Street, 3rd Floor, Boston, United States
Sunny3999
Sunny3999 Feb. 3 at 4:15 PM
$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ACET $PAVM $PMNT $RVPH
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:21 PM
$PMN Wow ripping with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ACET $PAVM $PMNT $RVPH
0 · Reply
aletz
aletz Jan. 30 at 1:14 PM
$ACET Feb Wk 1 AI Scanner https://www.biostockinfo.com/biotech-catalyst-ai-scanner-february-wk1/
1 · Reply
THSSKS
THSSKS Jan. 27 at 3:27 PM
$ACET started a small position here. It’s junk but $10+ in cash
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 27 at 2:12 AM
$ACET Current Stock Price: $8.66 Contracts to trade: $10 ACET Feb 20 2026 Call Entry: $0.50 Exit: $0.91 ROI: 84% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
pc247cz
pc247cz Jan. 26 at 3:49 PM
$ACET C'mon
0 · Reply
peepthestamp
peepthestamp Jan. 25 at 8:09 PM
$ACET $PAVM $PMN $PMNT $RVPH -Aging well 🫡
0 · Reply
BioTechChap
BioTechChap Jan. 22 at 9:51 PM
$ACET Matter of time until we see this one getting some traction
0 · Reply
StMichaelTwits
StMichaelTwits Jan. 22 at 9:20 PM
$WOK $ACET $SCWO @SwingScale How much are the bots paying you, $18-20 an hr. And of course you tell mommy you are a stock broker..🤣👇
0 · Reply
pc247cz
pc247cz Jan. 14 at 1:30 PM
$ACET I expect PUMP before another offering will be pursued.
0 · Reply
Latest News on ACET
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 30, 2026, 7:00 AM EST - 4 days ago

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Jan 7, 2026, 7:00 AM EST - 27 days ago

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Adicet Bio Announces Reverse Stock Split

Dec 26, 2025, 8:30 AM EST - 5 weeks ago

Adicet Bio Announces Reverse Stock Split

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 28, 2025, 2:23 PM EST - 2 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 4:01 PM EST - 3 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 31, 2025, 4:59 PM EDT - 3 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 12:35 PM EDT - 4 months ago

Adicet Bio, Inc. - Special Call

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 11:05 AM EDT - 4 months ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 7:01 AM EDT - 4 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Oct 7, 2025, 6:45 AM EDT - 4 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Aug 5, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:00 PM EDT - 9 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:01 PM EDT - 9 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 9 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 10 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Apr 17, 2025, 7:00 AM EDT - 10 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 5:12 PM EDT - 11 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 4:01 PM EST - 11 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Mar 3, 2025, 7:00 AM EST - 1 year ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 27, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Feb 5, 2025, 7:10 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Jan 8, 2025, 4:10 PM EST - 1 year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Sunny3999
Sunny3999 Feb. 3 at 4:15 PM
$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ACET $PAVM $PMNT $RVPH
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:21 PM
$PMN Wow ripping with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ACET $PAVM $PMNT $RVPH
0 · Reply
aletz
aletz Jan. 30 at 1:14 PM
$ACET Feb Wk 1 AI Scanner https://www.biostockinfo.com/biotech-catalyst-ai-scanner-february-wk1/
1 · Reply
THSSKS
THSSKS Jan. 27 at 3:27 PM
$ACET started a small position here. It’s junk but $10+ in cash
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 27 at 2:12 AM
$ACET Current Stock Price: $8.66 Contracts to trade: $10 ACET Feb 20 2026 Call Entry: $0.50 Exit: $0.91 ROI: 84% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
pc247cz
pc247cz Jan. 26 at 3:49 PM
$ACET C'mon
0 · Reply
peepthestamp
peepthestamp Jan. 25 at 8:09 PM
$ACET $PAVM $PMN $PMNT $RVPH -Aging well 🫡
0 · Reply
BioTechChap
BioTechChap Jan. 22 at 9:51 PM
$ACET Matter of time until we see this one getting some traction
0 · Reply
StMichaelTwits
StMichaelTwits Jan. 22 at 9:20 PM
$WOK $ACET $SCWO @SwingScale How much are the bots paying you, $18-20 an hr. And of course you tell mommy you are a stock broker..🤣👇
0 · Reply
pc247cz
pc247cz Jan. 14 at 1:30 PM
$ACET I expect PUMP before another offering will be pursued.
0 · Reply
Peterson28
Peterson28 Jan. 12 at 10:29 PM
$ACET Buying more everyday
1 · Reply
OHCF
OHCF Jan. 12 at 8:39 PM
$ACET oooh reverse split. I don't like it.
0 · Reply
Klamalsnn
Klamalsnn Jan. 7 at 12:48 PM
$ACET Update failed in Milestone delivery 26. postponemenz on all 2 Programms. Time to Leave
3 · Reply
_Emily_Johnson_
_Emily_Johnson_ Jan. 7 at 5:41 AM
$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk
0 · Reply
anachartanalyst
anachartanalyst Jan. 6 at 4:02 PM
$ACET https://anachart.com/wp-content/uploads/ana_temp/1767715304_soc-img.jpg
1 · Reply
PnLLogicX_1702
PnLLogicX_1702 Jan. 6 at 11:33 AM
$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk
0 · Reply
NEWBIGTECH
NEWBIGTECH Jan. 2 at 8:41 PM
$ACET funds moved to $SLS. 2 DRUGS, 20 + CANCERS for both. Look it up. @Sellaslife
0 · Reply
nnkr
nnkr Dec. 31 at 6:57 PM
$ACET I'm in another biotech (RIGL) that did 10:1 RS in June 2024. It's tripled since then, so not every RS is bad for the company's future.
0 · Reply
tr1llA
tr1llA Dec. 31 at 4:51 PM
$ACET nice up so far
0 · Reply
pc247cz
pc247cz Dec. 31 at 4:13 PM
$ACET is leaving the station 🫡
0 · Reply
pc247cz
pc247cz Dec. 31 at 3:11 PM
$INBS Congrats. $ACET could be next. And $AKTX is undisovered gem.
0 · Reply
smartmoney43
smartmoney43 Dec. 31 at 12:46 AM
$ACET tnxp went from 7 to 60 in 6 months. I guess anything is possible here
0 · Reply